Clinical-stage biotech company Accro Bioscience (Suzhou) Limited (Accropeutics) on Tuesday reported positive results from its Phase 2 clinical trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor for plaque psoriasis.

In the multi-centre, randomised, double-blind and placebo-controlled trial, 145 Chinese patients with moderate to severe plaque psoriasis received AC-201 25mg BID, 50mg BID or 100mg QD versus placebo. The primary endpoint was PASI-75 at Week 12.

The primary and key secondary endpoints were achieved following 12 weeks of treatment in all three dosing groups of AC-201.

Treatment with AC-201 was well tolerated. Treatment emergent adverse events were reported as mild to moderate, most commonly upper respiratory tract infection and hypertriglyceridemia.